HealthQuiet 28d · day 29
CD19 CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in Phase 1 Trial
A first-in-human trial used CD19 CAR T cells to deplete disease-driving B cells in six patients with treatment-refractory rheumatoid arthritis, with all six responding.
What to know
- A phase 1 trial used CD19 CAR T-cell therapy — engineered to deplete disease-driving B cells — in six patients with severe, treatment-refractory seropositive rheumatoid arthritis.
- All six patients showed a response, with coverage describing the outcome as substantial reduction in disease activity or remission.
- The result, published in Nature Medicine, extends CAR-T cell engineering, previously established mainly in blood cancers, into autoimmune disease treatment.
- The trial is small (six patients) and early-stage (phase 1), so durability and broader efficacy remain to be established in larger studies.
Phase 1 trial investigators Researchers conducting the CD19 CAR T-cell trialTrial patients (n=6) Participants with severe, seropositive, treatment-refractory rheumatoid arthritis
The record 6 articles and posts · last 29 days